Zeluvalimab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Zeluvalimab
- DrugBank Accession Number
- DB18868
- Background
Zeluvalimab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Anti-pd-1 monoclonal antibody amg 404
- Immunoglobulin g1 (295-cysteine,300-glycine,305-cysteine), anti-(human programmed cell death 1) (human monoclonal 20c1.009 mab .gamma.1-chain), disulfide with human monoclonal 20c1.009 mab .kappa.-chain, dimer
- Zeluvalimab (immunoglobulin g1-kappa, anti-(homo sapienspdcd1 (programmed cell death 1, pd-1, pd1, cd279)), monoclonal antibody)
- External IDs
- AMG 404
- AMG-404
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DX474PAV6P
- CAS number
- 2315361-37-4
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Active Not Recruiting Treatment Small Cell Lung Cancer (SCLC) 1 somestatus stop reason just information to hide 1 Completed Treatment Acute Lymphoblastic Leukemia (ALL) 1 somestatus stop reason just information to hide 1 Completed Treatment Advanced Solid Tumors 2 somestatus stop reason just information to hide 1 Completed Treatment Glioblastoma or Malignant Glioma 1 somestatus stop reason just information to hide 1 Recruiting Treatment Advanced Solid Tumors / Kirsten Rat Sarcoma (KRAS) pG12C Mutation 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at June 26, 2024 20:37 / Updated at June 29, 2024 07:29